Cargando…
Decalogue for the selection of oral antibiotics for lower respiratory tract infections
Lower respiratory tract infections, including chronic obstructive pulmonary disease exacerbations (COPD-E) and community acquired pneumonia (CAP), are one of the most frequent reasons for consultation in primary care and hospital emergency departments, and are the cause of a high prescription of ant...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790641/ https://www.ncbi.nlm.nih.gov/pubmed/35041328 http://dx.doi.org/10.37201/req/172.2021 |
_version_ | 1784640061302636544 |
---|---|
author | Cantón, Rafael Barberán, José Linares, Manuel Molero, José María RodríguezGonzález-Moro, José Miguel Salavert, Miguel del Castillo, Juan González |
author_facet | Cantón, Rafael Barberán, José Linares, Manuel Molero, José María RodríguezGonzález-Moro, José Miguel Salavert, Miguel del Castillo, Juan González |
author_sort | Cantón, Rafael |
collection | PubMed |
description | Lower respiratory tract infections, including chronic obstructive pulmonary disease exacerbations (COPD-E) and community acquired pneumonia (CAP), are one of the most frequent reasons for consultation in primary care and hospital emergency departments, and are the cause of a high prescription of antimicrobial agents. The selection of the most appropriate oral antibiotic treatment is based on different aspects and includes to first consider a bacterial aetiology and not a viral infection, to know the bacterial pathogen that most frequently cause these infections and the frequency of their local antimicrobial resistance. Treatment should also be prescribed quickly and antibiotics should be selected among those with a quicker mode of action, achieving the greatest effect in the shortest time and with the fewest adverse effects (toxicity, interactions, resistance and/or ecological impact). Whenever possible, antimicrobials should be rotated and diversified and switched to the oral route as soon as possible. With these premises, the oral treatment guidelines for mild or moderate COPD-E and CAP in Spain include as first options beta-lactam antibiotics (amoxicillin and amoxicillin-clavulanate and cefditoren), in certain situations associated with a macrolide, and relegating fluoroquinolones as an alternative, except in cases where the presence of Pseudomonas aeruginosa is suspected. |
format | Online Article Text |
id | pubmed-8790641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Sociedad Española de Quimioterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-87906412022-02-07 Decalogue for the selection of oral antibiotics for lower respiratory tract infections Cantón, Rafael Barberán, José Linares, Manuel Molero, José María RodríguezGonzález-Moro, José Miguel Salavert, Miguel del Castillo, Juan González Rev Esp Quimioter Review Lower respiratory tract infections, including chronic obstructive pulmonary disease exacerbations (COPD-E) and community acquired pneumonia (CAP), are one of the most frequent reasons for consultation in primary care and hospital emergency departments, and are the cause of a high prescription of antimicrobial agents. The selection of the most appropriate oral antibiotic treatment is based on different aspects and includes to first consider a bacterial aetiology and not a viral infection, to know the bacterial pathogen that most frequently cause these infections and the frequency of their local antimicrobial resistance. Treatment should also be prescribed quickly and antibiotics should be selected among those with a quicker mode of action, achieving the greatest effect in the shortest time and with the fewest adverse effects (toxicity, interactions, resistance and/or ecological impact). Whenever possible, antimicrobials should be rotated and diversified and switched to the oral route as soon as possible. With these premises, the oral treatment guidelines for mild or moderate COPD-E and CAP in Spain include as first options beta-lactam antibiotics (amoxicillin and amoxicillin-clavulanate and cefditoren), in certain situations associated with a macrolide, and relegating fluoroquinolones as an alternative, except in cases where the presence of Pseudomonas aeruginosa is suspected. Sociedad Española de Quimioterapia 2022-01-20 2022 /pmc/articles/PMC8790641/ /pubmed/35041328 http://dx.doi.org/10.37201/req/172.2021 Text en © The Author 2022 https://creativecommons.org/licenses/by-nc/4.0/Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). |
spellingShingle | Review Cantón, Rafael Barberán, José Linares, Manuel Molero, José María RodríguezGonzález-Moro, José Miguel Salavert, Miguel del Castillo, Juan González Decalogue for the selection of oral antibiotics for lower respiratory tract infections |
title | Decalogue for the selection of oral antibiotics for lower respiratory tract infections |
title_full | Decalogue for the selection of oral antibiotics for lower respiratory tract infections |
title_fullStr | Decalogue for the selection of oral antibiotics for lower respiratory tract infections |
title_full_unstemmed | Decalogue for the selection of oral antibiotics for lower respiratory tract infections |
title_short | Decalogue for the selection of oral antibiotics for lower respiratory tract infections |
title_sort | decalogue for the selection of oral antibiotics for lower respiratory tract infections |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790641/ https://www.ncbi.nlm.nih.gov/pubmed/35041328 http://dx.doi.org/10.37201/req/172.2021 |
work_keys_str_mv | AT cantonrafael decaloguefortheselectionoforalantibioticsforlowerrespiratorytractinfections AT barberanjose decaloguefortheselectionoforalantibioticsforlowerrespiratorytractinfections AT linaresmanuel decaloguefortheselectionoforalantibioticsforlowerrespiratorytractinfections AT molerojosemaria decaloguefortheselectionoforalantibioticsforlowerrespiratorytractinfections AT rodriguezgonzalezmorojosemiguel decaloguefortheselectionoforalantibioticsforlowerrespiratorytractinfections AT salavertmiguel decaloguefortheselectionoforalantibioticsforlowerrespiratorytractinfections AT delcastillojuangonzalez decaloguefortheselectionoforalantibioticsforlowerrespiratorytractinfections |